- PR Newswire•7 months agoAVAX Technologies Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase 1/2 Clinical Trial In Patients With Relapsed Stage III Or IV Ovarian Cancer.
PHILADELPHIA, Jan. 26, 2016 /PRNewswire/ -- AVAX Technologies, Inc. (AVXT), a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV Ovarian Cancer. The overall design is a Phase I/II, double-blind, three-dose regimen, multi-centered, trial in patients with stage III or stage IV ovarian carcinoma who have undergone de-bulking followed by intra-peritoneal chemotherapy. Study Endpoints were treatment-emergent and related adverse events, serious adverse events, and grade 3 and 4 laboratory abnormalities for safety assessment, DTH responses to DNP-modified and unmodified autologous ovarian cancer cells.
- PR Newswire•10 months ago
PHILADELPHIA, Oct. 19, 2015 /PRNewswire/ -- AVAX Technologies, Inc. (AVXT), a pioneer and leader in the clinical development and production of autologous cancer immunotherapy vaccines, is pleased to announce the expansion of its executive team with the appointment of Adele Sommerfeld as Chief Executive Officer. Ms. Sommerfeld joins the AVAX management team with a breadth of experience within the biotechnology industry, spanning over 25 years. She brings significant experience across functional areas including biotechnology equity financing transactions, corporate strategy, strategic partnering, and business development. Ms. Sommerfeld has a MBA and M.Sc.
We're sorry this is all we were able to find about this topic.
AVAX Technologies Inc. (AVXT)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.01 - 0.01|
|52wk Range||0.00 - 0.04|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.15|
|Avg Vol (3m)||87,813|
|Dividend & Yield||N/A (N/A)|